Leading the way in psychiatry real-world evidence
Osmind is a recognized leader in psychiatry research, partnering with academic groups, mental health nonprofits and foundations, government stakeholders, biopharmaceutical companies, and medical device companies.
Our research has made an impact across interventional psychiatry and precision mental health, having contributed directly to regulatory decision making, clinician practice guidelines, state and federal policymaking, and clinical development planning.
Psychedelics: Preparing Your Clinic
Huang, L. (2026). Psychedelics: Preparing Your Clinic. National Council for Mental Wellbeing Annual Meeting.
Beyond the RCT: Real-World Evidence on Ketamine for PTSD and Depression.
Sauve, W., Dougherty, R., Qian J. (2026). Beyond the RCT: Real-World Evidence on Ketamine for PTSD and Depression. SAMHSA Psychedelic Brown Bag session.
Psychometric Evaluation of the DSM-5-TR-Level 1 Cross-Cutting Symptom Measure: Transdiagnostic Factor Analysis in a Real-world Psychiatric Outpatient Sample
Macmillan, C., Gogtay, N., Gibson, D., Qian, J. J., Sauvé, W. M., & Shih, E. (2026). Psychometric evaluation of the DSM-5-TR-Level 1 Cross-Cutting Symptom Measure: Transdiagnostic factor analysis in a real-world psychiatric outpatient sample. Frontiers in Psychiatry, 17. doi: 10.3389/fpsyt.2026.1680352
Read more
Regulatory, Reimbursement, and Health System Considerations: Rapid-Acting Psychopharmacologic Interventions
Huang, L. and Qian, J. (2026). National Institutes of Health workshop – Rapid-Acting Psychopharmacologic Interventions From Evidence to Implementation: Research Design, Data Standards, and Scalable Models of Care.
Novel strategies for ABI neurorehabilitation and neurobehavioral recovery
O'Shanick, G., & Sauvé, W. (2026). Neuromodulation: Novel strategies for ABI neurorehabilitation and neurobehavioral recovery. Interactive workshop presented at the North American Brain Injury Society (NABIS) 18th Annual Conference on Brain Injury, March 2026.
Psilocybin services and mental health outcomes within Oregon’s state-regulated model
Gow, A., Shih, E., Reid, R., Qian, J. J., Mellor, C., McInnes, L. A., Carhart-Harris, R., & Davis, J. N. (2026). Psilocybin services and mental health outcomes within Oregon's state-regulated model. *medRxiv* 2026.
Read more
Ketamine Infusion Therapy for PTSD: Real World Outcomes in over 8,000 patients
McInnes, L. A., Berman, R. M., & Shih, E. (2026). Ketamine infusion therapy for PTSD: Real-world outcomes in over 8,000 patients. Symposium presentation at the ASKP Annual Meeting, January 2026.
Differential Associations of Body Mass Index with Depression, Anxiety, and PTSD Symptom Trajectories in Patients Receiving Ketamine Infusion Therapy in the Real World
Sauvé, W., McIntyre, R., Qian, J., McInnes, L.A., Berman, R.M., Shih, E. (2025). Differential Associations of Body Mass Index with Depression, Anxiety, and PTSD Symptom Trajectories in Patients Receiving Ketamine Infusion Therapy in the Real World. Poster presented at ACNP Annual Meeting, Paradise Island, Bahamas.
Read more
Psychedelics care delivery infrastructure
Huang, L., Qian, J., Sauvé, W., Cantor Fitzgerald webinar series
Integrating Psychedelics Into the US Healthcare System: Insights From Interventional Psychiatry Practices and Legal Psilocybin Services in Oregon
Qian, J., CNS Summit, Boston, MA
Real-world Outcomes of Facilitated Psilocybin Sessions under Oregon's Legal Framework
Davis, J., Gow, A., Reid, R., Shih, E., Qian, J.J., McInnes, L.A., Sauve, W.M., Carhart-Harris, R. (2025). Real-world Outcomes of Facilitated Psilocybin Sessions under Oregon's Legal Framework. Poster presented at Psych Congress 2025, San Diego, CA.
Read more
Real-World Evidence from Oregon's Legal Psilocybin Services: First Systematic Study of Demographics and Access Patterns
Davis, J., Gow, A., Reid, R., Shih, E., Qian, J.J., McInnes, L.A., Sauve, W.M., Carhart-Harris, R. (2025). Real-world Evidence from Facilitated Psilocybin Sessions within Oregon's Legal Framework: Demographics, Engagement, and Motivations. Poster presented at Psych Congress 2025, San Diego, CA.
Read more
A Retrospective Analysis of Ketamine Intravenous Therapy for PTSD in Real-World Care Settings
McInnes, L. A., Berman, R. M., Worley, M. J., & Shih, E. (2025, October). Psychiatry Research, 352, 116689.
Read more
Can the DSM-5 TR Level 1 Cross-Cutting Measure Cut it Transdiagnostically in the Real World?
MacMillan, C., Shih, E., Qian, J., Gogtay, N., & Gibson, D. (2025, May). American Psychiatric Association Annual Meeting, San Francisco, CA.
Read more
Advancing Learning Health Systems and Interventional Psychiatry as Force Multipliers
Sauve, W. American Psychiatry Association 2025 Annual Meeting
A Retrospective Analysis of Ketamine Intravenous Therapy for PTSD in Real-World Care Settings
McInnes, A. A., Berman, R. M., Worley, M. J., & Shih, E. (2025). American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3)
Read more
A Retrospective Analysis of Ketamine Intravenous Therapy for PTSD in Real-World Care Settings (presented at ACNP)
McInnes, L. A., Berman, R. M., Worley, M. J., & Shih, E. (2024), American College of Neuropsychopharmacology
Read more
Examining the Factor Structure of the Transdiagnostic DSM-5-TR Level 1 Cross-Cutting Symptom Measure in Real World Psychiatric Outpatients
MacMillan, C., Shih, E., Worley, M., Kane, G., Qian, J., McInnes, L. A., Gogtay, N., & Gibson, D. (2024), American College of Neuropsychopharmocology
Read more
Leveraging a Learning Health System to Implement the DSM-5-TR Level 1 Cross-Cutting Measure
MacMillan, C., Qian, J., McInnes, L. A., Worley, M., Muir, O., Gogtay, N., & Gibson, D. (2024), CNS Summit
Read more
Accelerated dTMS Utilization of H7 Coil for Comorbid TRD: A Case Series
Aslam, MacMillan, Muir (2024). Clinical TMS Society Annual Meeting.
Utilizing nVNS Treatment Effectively After Non-Response to Accelerated H7 and H1 Treatment in Highly Refractory Depression: A Case Report
Aslam, MacMillan, Muir (2024) Clinical TMS Society Annual Meeting.
Successful dTMS in rTMS, ECT, and Ketamine Refractory Depression: A Case Series
Aslam, Handoo, MacMillan, Muir (2024). Clinical TMS Society Annual Meeting.
Peril and Promise: Teens, Tech, and America’s Mental Health Crisis
Belfort, MacMillan, Weigle (2024). Child and Adolescent Psychiatric Clinics of North America.
Read more
Impact of duration of esketamine nasal spray treatment on change in depression symptoms in real-world patients
McInnes, Joshi, Kane, et al. (2024). American Society of Clinical Psychopharmacology Annual Meeting.
Read more
A retrospective study of real-world outcomes for esketamine nasal spray among patients with treatment resistant depression
McInnes, Joshi, Kane, et al. (2024). American Society of Clinical Psychopharmacology Annual Meeting.
Read more
Comparative Effectiveness of Ketamine Intravenous Therapy and Intranasal Esketamine for Depression in Real-world Settings
McInnes and Kane (2024). American Society of Clinical Psychopharmacology Annual Meeting.
Read more
Psychiatric Treatments that have FDA’s Breakthrough Therapy Status
MacMillan (2024). American Psychiatric Association Annual Meeting.
Measurement Based Care Learning Lab
MacMillan (2024). American Psychiatric Association Annual Meeting.
A phase 2 trial with CLE-100 oral esketamine for patients with MDD and inadequate response to antidepressant during COVID-19 pandemic
Hagai et al. (2024). Oxford Ketamine Conference.
Considering New and Emerging Treatment Strategies for Depression: Beyond STAR*D and the Monoamines
McInnes and Marton (2024). Current Psychiatry Research and Reviews.
Read more
Embracing pragmatism for ketamine insurance coverage: Leveraging real-world evidence
McInnes, Marton, Qian (2024). Journal of Affective Disorders.
Read more
Machine Learning (ML) Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy (KIT)
Kane, Worley, McInnes (2023). American Society of Ketamine Physicians, Psychotherapists & Practitioners Annual Meeting.
Using a longitudinal model to predict outcomes to ketamine intravenous therapy for depression
Kane, Worley, McInnes (2023). American College of Neuropharmacology Annual Meeting.
Read more
Learning to Unlearn: the role of psychedelic assisted therapy in serious mental illness featuring substance use disorders, PTSD, and depression.
McInnes, A. and Qian, J. (2023). Learning to Unlearn: the role of psychedelic assisted therapy in serious mental illness featuring substance use disorders, PTSD, and depression. Mental Health Association of Alameda County Annual Conference.
Real world efficacy and safety of various accelerated deep TMS protocols for major depression
Roth, Hanlon, Pell et al. (2024). Psychiatric Research.
Read more
The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis
Hietamies, McInnes, Klise et al. (2023). Journal of Affective Disorders.
Read more
Prediction of treatment adherence to ketamine infusion therapy
Kane, Worley, Oldenkamp et al. (2023). Psychedelic Science.
Read more
CLEO: A Phase 2 Randomized Controlled Adjunctive Treatment Trial with CLE-100 Esketamine Tablet for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants, During The COVID-19 Pandemic
Fava, Berkowitz, Mathew et al. (2023). American Society of Clinical Psychopharmacology Annual Meeting.
A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings
McInnes, Qian, Gargeya et al. (2022). Journal of Affective Disorders.
Read more
REMS in Interventional Psychiatry: A Case Study in Innovation
Qian and MacMillan (2021). REMS Innovation Summit.
A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings
McInnes, Qian, Gargeya et al. (2021). Psychedelic Therapeutics and Drug Development Conference.
Psychedelic medicine in child and adolescent psychiatry: an analysis of risks and benefits
Qian and Nattagh (2021). Klingenstein Child Psychiatry Annual Conference.
If you, or someone you know, is in crisis or needs immediate assistance, please call 911 immediately. To talk to someone now, please call the National Suicide Prevention Lifeline at 1-800-273-8255 or 988.
Osmind © 2026 All Rights Reserved.